Human Reproduction Update, Vol.8, No.6 pp.559-577, 2002
© European Society of Human Reproduction and Embryology 2002; all rights reserved
Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review
1 IVF Centre, Department of Obstetrics-Gynaecology, University Hospital St Pierre (Free University of Brussels ULB), Belgium
To whom correspondence should be addressed at: Annick Delvigne, IVF Centre, Department of Obstetrics-Gynaecology, Free University of Brussels (ULB), St Peter Hospital, rue Haute 322, B-1000 Brussels, Belgium. e-mail: annickdelvigne{at}swing.be
Abstract
Ovarian hyperstimulation syndrome (OHSS) is a rare iatrogenic complication of ovarian stimulation occurring during the luteal phase or during early pregnancy. Fortunately, the reported prevalence of the severe form of OHSS is small, ranging from 0.5 to 5%. Nevertheless, as this is an iatrogenic complication of a non-vital treatment with a potentially fatal outcome, the syndrome remains a serious problem for specialists dealing with infertility. The aim of this literature review was to determine whether it is possible to identify patients at risk, and which preventive method should be applied when an exaggerated ovarian response occurs. Data pertaining to the epidemiology and prevention of OHSS in women were searched using Medline, Current Contents and PubMed, and are summarized. Preventive strategies attempt either to limit the dose or concentration of hCG or to find a way to induce luteolysis without inducing a detrimental effect on endometrial and oocyte quality. The following particular preventive strategies were reviewed: cancelling the cycle; coasting; early unilateral ovarian follicular aspiration (EUFA); modifying the methods of ovulation triggering; administration of glucocorticoids, macromolecules and progesterone; cryopreservation of all embryos; and electrocautery or laser vaporization of one or both ovaries.
Key words: coasting / IVF / OHSS / prevention / treatment
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Aramwit, K. Pruksananonda, N. Kasettratat, and K. Jammeechai Risk factors for ovarian hyperstimulation syndrome in Thai patients using gonadotropins for in vitro fertilization Am. J. Health Syst. Pharm., June 15, 2008; 65(12): 1148 - 1153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B.C.J.M. Fauser, K. Diedrich, P. Devroey, and on behalf of the Evian Annual Reproduction (EVAR) Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation Hum. Reprod. Update, January 1, 2008; 14(1): 1 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Alvarez, I. Alonso-Muriel, G. Garcia, J. Crespo, J. Bellver, C. Simon, and A. Pellicer Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study Hum. Reprod., December 1, 2007; 22(12): 3210 - 3214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Nelson, R. W. Yates, and R. Fleming Serum anti-Mullerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles implications for individualization of therapy Hum. Reprod., September 1, 2007; 22(9): 2414 - 2421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Alvarez, L. Marti-Bonmati, E. Novella-Maestre, R. Sanz, R. Gomez, M. Fernandez-Sanchez, C. Simon, and A. Pellicer Dopamine Agonist Cabergoline Reduces Hemoconcentration and Ascites in Hyperstimulated Women Undergoing Assisted Reproduction J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 2931 - 2937. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E.M. Kolibianakis, J. Collins, B.C. Tarlatzis, P. Devroey, K. Diedrich, and G. Griesinger Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis Hum. Reprod. Update, November 1, 2006; 12(6): 651 - 671. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. B. Sheehan, M. Lane, and D. K. Gardner The CryoLoop facilitates re-vitrification of embryos at four successive stages of development without impairing embryo growth Hum. Reprod., November 1, 2006; 21(11): 2978 - 2984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.C. Tarlatzis, B.C. Fauser, E.M. Kolibianakis, K. Diedrich, P. Devroey, and , On Behalf of the Brussels GnRH Antagonist Consen GnRH antagonists in ovarian stimulation for IVF Hum. Reprod. Update, July 1, 2006; 12(4): 333 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Macklon, R. L. Stouffer, L. C. Giudice, and B. C. J. M. Fauser The Science behind 25 Years of Ovarian Stimulation for in Vitro Fertilization Endocr. Rev., April 1, 2006; 27(2): 170 - 207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Van Voorhis Outcomes From Assisted Reproductive Technology Obstet. Gynecol., January 1, 2006; 107(1): 183 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E.M.E.W. Heijnen, M.J.C. Eijkemans, E.G. Hughes, J.S.E. Laven, N.S. Macklon, and B.C.J.M. Fauser A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome Hum. Reprod. Update, January 1, 2006; 12(1): 13 - 21. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. C. Ajonuma, L. L. Tsang, G. H. Zhang, C. H. Y. Wong, M. C. Lau, L. S. Ho, D. K. Rowlands, C. X. Zhou, C. P. Ng, J. Chen, et al. Estrogen-Induced Abnormally High Cystic Fibrosis Transmembrane Conductance Regulator Expression Results in Ovarian Hyperstimulation Syndrome Mol. Endocrinol., December 1, 2005; 19(12): 3038 - 3044. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Mansour, M. Aboulghar, G. Serour, Y. Amin, and A. M. Abou-Setta Criteria of a successful coasting protocol for the prevention of severe ovarian hyperstimulation syndrome Hum. Reprod., November 1, 2005; 20(11): 3167 - 3172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B Rulli and I. Huhtaniemi What have gonadotrophin overexpressing transgenic mice taught us about gonadal function? Reproduction, September 1, 2005; 130(3): 283 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ragni, W. Vegetti, A. Riccaboni, B. Engl, C. Brigante, and P.G. Crosignani Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome Hum. Reprod., September 1, 2005; 20(9): 2421 - 2425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Orvieto Can we eliminate severe ovarian hyperstimulation syndrome? Hum. Reprod., February 1, 2005; 20(2): 320 - 322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Daelemans, G. Smits, V. de Maertelaer, S. Costagliola, Y. Englert, G. Vassart, and A. Delbaere Prediction of Severity of Symptoms in Iatrogenic Ovarian Hyperstimulation Syndrome by Follicle-Stimulating Hormone Receptor Ser680Asn Polymorphism J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6310 - 6315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Phy, C. A. Conover, D. H. Abbott, M. A. Zschunke, D. L. Walker, D. R. Session, I. S. Tummon, A. R. Thornhill, T. G. Lesnick, and D. A. Dumesic Insulin and Messenger Ribonucleic Acid Expression of Insulin Receptor Isoforms in Ovarian Follicles from Nonhirsute Ovulatory Women and Polycystic Ovary Syndrome Patients J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3561 - 3566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.A. Garcia-Velasco, A. Zuniga, A. Pacheco, R. Gomez, C. Simon, J. Remohi, and A. Pellicer Coasting acts through downregulation of VEGF gene expression and protein secretion Hum. Reprod., July 1, 2004; 19(7): 1530 - 1538. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Levin, R. Gamzu, Y. Hasson, J.B. Lessing, A. Amit, I. Shapira, S. Berliner, and B. Almog Increased erythrocyte aggregation in ovarian hyperstimulation syndrome: a possible contributing factor in the pathophysiology of this disease Hum. Reprod., May 1, 2004; 19(5): 1076 - 1080. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Delbaere, G. Smits, O. Olatunbosun, R. Pierson, G. Vassart, and S. Costagliola New insights into the pathophysiology of ovarian hyperstimulation syndrome. What makes the difference between spontaneous and iatrogenic syndrome? Hum. Reprod., March 1, 2004; 19(3): 486 - 489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Smits, O. Olatunbosun, A. Delbaere, R. Pierson, G. Vassart, and S. Costagliola Ovarian Hyperstimulation Syndrome Due to a Mutation in the Follicle-Stimulating Hormone Receptor N. Engl. J. Med., August 21, 2003; 349(8): 760 - 766. [Full Text] [PDF]
|
|